Literature DB >> 32188987

Way to Go/No-Go!

Glenn J Lesser1.   

Abstract

Mesh:

Year:  2020        PMID: 32188987      PMCID: PMC7229245          DOI: 10.1093/neuonc/noaa061

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  6 in total

1.  Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide.

Authors:  Stuart A Grossman; Xiaobu Ye; Glenn Lesser; Andrew Sloan; Hetty Carraway; Serena Desideri; Steven Piantadosi
Journal:  Clin Cancer Res       Date:  2011-07-07       Impact factor: 12.531

2.  Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial.

Authors:  Patrick Y Wen; Mehdi Touat; Brian M Alexander; Ingo K Mellinghoff; Shakti Ramkissoon; Christine S McCluskey; Kristine Pelton; Sam Haidar; Sankha S Basu; Sarah C Gaffey; Loreal E Brown; Juan Emmanuel Martinez-Ledesma; Shaofang Wu; Jungwoo Kim; Wei Wei; Mi-Ae Park; Jason T Huse; John G Kuhn; Mikael L Rinne; Howard Colman; Nathalie Y R Agar; Antonio M Omuro; Lisa M DeAngelis; Mark R Gilbert; John F de Groot; Timothy F Cloughesy; Andrew S Chi; Thomas M Roberts; Jean J Zhao; Eudocia Q Lee; Lakshmi Nayak; James R Heath; Laura L Horky; Tracy T Batchelor; Rameen Beroukhim; Susan M Chang; Azra H Ligon; Ian F Dunn; Dimpy Koul; Geoffrey S Young; Michael D Prados; David A Reardon; W K Alfred Yung; Keith L Ligon
Journal:  J Clin Oncol       Date:  2019-02-04       Impact factor: 44.544

Review 3.  The art of gene therapy for glioma: a review of the challenging road to the bedside.

Authors:  Alex Tobias; Atique Ahmed; Kyung-Sub Moon; Maciej S Lesniak
Journal:  J Neurol Neurosurg Psychiatry       Date:  2012-09-19       Impact factor: 10.154

Review 4.  Uncertainty in the translation of preclinical experiments to clinical trials. Why do most phase III clinical trials fail?

Authors:  Pedro R Lowenstein; Maria G Castro
Journal:  Curr Gene Ther       Date:  2009-10       Impact factor: 4.391

5.  A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE).

Authors:  Timothy F Cloughesy; Andrew Brenner; John F de Groot; Nicholas A Butowski; Leor Zach; Jian L Campian; Benjamin M Ellingson; Laurence S Freedman; Yael C Cohen; Noa Lowenton-Spier; Tamar Rachmilewitz Minei; Shifra Fain Shmueli; Patrick Y Wen
Journal:  Neuro Oncol       Date:  2020-05-15       Impact factor: 12.300

6.  Safety and efficacy of VB-111, an anticancer gene therapy, in patients with recurrent glioblastoma: results of a phase I/II study.

Authors:  Andrew J Brenner; Katherine B Peters; James Vredenburgh; Felix Bokstein; Deborah T Blumenthal; Shlomit Yust-Katz; Idit Peretz; Bernice Oberman; Laurence S Freedman; Benjamin M Ellingson; Timothy F Cloughesy; Naamit Sher; Yael C Cohen; Noa Lowenton-Spier; Tamar Rachmilewitz Minei; Niva Yakov; Itzhak Mendel; Eyal Breitbart; Patrick Y Wen
Journal:  Neuro Oncol       Date:  2020-05-15       Impact factor: 12.300

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.